重症病毒性肝炎61例疗效分析

对61例各型重症病毒性肝炎(以下简称重肝)采用一般支持疗法、综合疗法、综合疗法加山茛菪碱治疗。结果:后两组病死率分别为42.86％、31.82％,明显低于一般支持疗法组病死率(88.89％P<0.01)。死亡病例平均存活时间亦较一般支持疗法明显延长。并发症减少。且综合疗法加山茛菪碱可降低慢重肝死亡率,优于一般疗法与单纯综合治疗组。

A CLINICAL REPORT OF TREATMENT ON 61 CASES WITH SEVERE VIRAL-HEPAITIS

61 cases with fulminant hepatitis were treated with traditional therapy (Group Ⅰ), combined therapy (Group Ⅱ) and combined therapy with anisodamine (Group) Ⅲ respectively. The results showed that the mortality of group Ⅱ(42.86%) and group Ⅲ(31.82%) was much lower thau than of group Ⅰ (88.89%). P<0.01; compared with group Ⅰ the incidence of complications was lower and the average survival time of the dead cases in much longer in group Ⅱ and group Ⅲ; The mortality of chronic fulminant hepatitis in group Ⅲ was lower than that of group Ⅰ (P<0.01) and group Ⅱ (P<0.05)